Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sitagliptin - Merck & Co

Drug Profile

Sitagliptin - Merck & Co

Alternative Names: Glactiv; Januvia; MK-0431; MK-431; ONO-5435; Tesavel; Xelevia

Latest Information Update: 31 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; Merck Sharp & Dohme
  • Developer Banyu; Merck & Co; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer; University of Colorado at Denver; Washington University School of Medicine
  • Class Antihyperglycaemics; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 17 Jul 2019 Merck completes a phase II trial for Type 2 diabetes mellitus in Germany (PO) (NCT03359590)
  • 01 Dec 2018 Merck completes a phase II trial in Italy (NCT01336322)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top